57.85
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TVTX?
Forum
Prognose
Aktiensplit
Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten
Will Travere’s Removal From Key Russell Value Indices Change Travere Therapeutics' (TVTX) Narrative? - simplywall.st
Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib - The Manila Times
Travere Therapeutics Wins Much-Awaited Approval For Drug In Rare Kidney Disease - Stocktwits
Travere Therapeutics: Filspari Is Becoming A Rare Kidney Disease Platform (NASDAQ:TVTX) - Seeking Alpha
TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits
Travere Therapeutics Receives Notice of Allowance from the U.S. P - The National Law Review
Travere Therapeutics, Inc.(NasdaqGM: TVTX) dropped from Russell 2000 Value Benchmark - marketscreener.com
Understanding Momentum Shifts in (TVTX) - Stock Traders Daily
Travere Therapeutics, Inc.(NasdaqGM:TVTX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment - Stocktwits
Enterprise value to revenue forward of Travere Therapeutics, Inc. – NASDAQ:TVTX - TradingView
Price to earnings forward of Travere Therapeutics, Inc. – NASDAQ:TVTX - TradingView
Travere Therapeutics, Inc.(NasdaqGM: TVTX) dropped from Russell 3000 Value Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Travere Therapeutics, Inc. – NASDAQ:TVTX - TradingView
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Thera - The National Law Review
Price to sales forward of Travere Therapeutics, Inc. – NASDAQ:TVTX - TradingView
Travere Therapeutics, Inc. Actuals & Estimates (NASDAQ:TVTX) - TradingView
TVTX Maintained by Guggenheim -- Price Target Raised to $65 - GuruFocus
TVTX Forecast — Price Target — Prediction for 2027 - TradingView
Travere Therapeutics stock hits 52-week high at 56.9 USD By Investing.com - Investing.com Australia
Travere Therapeutics stock hits 52-week high at 56.9 USD - Investing.com
Travere Therapeutics Inc (TVTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Travere Therapeutics Inc (TVTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Form 4 Travere Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa
Travere Therapeutics (NASDAQ: TVTX) CMO gifts 468 shares in Form 4 - Stock Titan
TVTX Maintains by Wedbush -- Price Target Raised to $61.00 - GuruFocus
Travere Therapeutics Shows Favorable Setup With Filspari as Growth Asset, Wedbush Says - marketscreener.com
Travere and Everest Medicines Strike $1.1 Billion Rare Kidney Disease Deal - The Healthcare Technology Report.
A Quick Look at Today's Ratings for Travere Therapeutic(TVTX.US), With a Forecast Between $49 to $67 - Moomoo
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
TVTX Maintained by Evercore ISI Group -- Price Target Raised to $60 - GuruFocus
Travere Therapeutics Inc (TVTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Travere Therapeutics Inc (TVTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Travere Therapeutics Inc (TVTX) Institutional Confidence - TradingKey
Travere Therapeutics stock hits 52-week high at 54.49 USD By Investing.com - Investing.com Nigeria
Travere Therapeutics Inc (TVTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Travere Therapeutics Inc (TVTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Avoiding Lag: Real-Time Signals in (TVTX) Movement - Stock Traders Daily
Travere Therapeutics Inc (TVTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Travere Therapeutics Announces R&D Leadership Transition Plan - The Globe and Mail
Travere Therapeutics stock hits 52-week high at 54.49 USD - Investing.com
Travere Therapeutics announces leadership changes in R&D By Investing.com - Investing.com South Africa
Travere Therapeutics, Inc. (TVTX) latest stock news and headlines - Yahoo Finance Singapore
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):